Type 2 diabetes: Prevention of a population-wide illness and its consequences;Type 2-diabetes: Forebyggelse af en folkesygdom og dens konsekvenser

Ugeskrift for Laeger

Volumn 166, Issue 14, 2004, Pages 1316-1320

  Borch Johnsen, Knut ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; INSULIN; ORAL ANTIDIABETIC AGENT; STATINE DERIVATIVE;

COUNSELING; DENMARK; DIABETES CONTROL; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; POLYPHARMACY; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SEX DIFFERENCE; TECHNOLOGY;

DENMARK; DIABETES MELLITUS, TYPE 2; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; PREVALENCE; PRIMARY PREVENTION; PUBLIC HEALTH; RISK FACTORS;

EID: 1842429703     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Sundhedsstyrelsen. Type 2-diabetes: Medicinsk teknologivurdering af screening, diagnostik og behandling. Medicinsk Teknologivurdering 2003;5.
2. Indenrigs- og Sundhedsministeriet, Handlingsplan om diabetes, 2003.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: numerical estimates and projections. Diabetes Care 1998;21:1414-31.
4. Glümer C, Jørgensen T, Borch-Johnsen K. Prevalence of diabetes and impaired glucose regulation in a Danish population - The Inter99 study. Diabetes Care 2003;26:2335-40.
5. Drivsholm T, Ibsen H, Schroll M et al. Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year old Danes. Diabetic Medicine 2001;18:126-32.
6. The Decode Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Archive of Internal Medicine 2001;161:397-404.
7. Alberti KGMM, Zimmett PZ for a WHO consultation: definition, diagnosis and classification of diabetes mellitus and its complications; Part 1: Diagnosis and classification of diabetes mellitus. Genève: World Health Organisation, 1999.
8. Balkau B, Drivsholm T, Borch-Johnsen K et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
9. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
10. Zimmet PZ. Kelly West Lecture 1991: challenges in diabetes epidemiology: from West to the rest. Diabetes Care 1992;15:232-52.
11. Manson JE, Spelsberg A. Primary prevention of non-insulin-dependent diabetes mellitus. Am J Prev Med 1994;10:172-84.
12. Hu FB, Manson JE, Stampfer MJ et al. Diet, lifestyle and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-97.
13. O'Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aboriginies after temporary reversion to traditional lifestyle. Diabetes 1984;33:596-603.
14. Puska P, Nissinen A, Tuomilehto J et al. The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Annu. Rev Public Health 1985;6:147-93.
15. Maccoby N, Farquhar JW, Wood PD et al. Reducing the risk of cardiovascular disease: effects of a community-based campaign on knowledge and behavior. J Community Health 1977;3:100-14.
16. Murray RP, Connett JE, Rand CS et al. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev Med 2002;35:314-9.
17. Pan X, Li G, Hu Y et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care 1997;20;537-44.
18. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in life style among subjects with impaired glucose tolerance. N Engl J Med 2001;333:1343-50.
19. Knowler WC, Barrett-Connor E, Fowler SE et al; Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
20. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
21. Jørgensen T, Borch-Johnsen K, Thomsen TF et al. A randomized non-pharmacological intervention study for prevention of ischemic heart disease. Baseline results Inter99. Eur J Cardiovascular Prevention and Rehabilitation 2003;10:377-86.
22. Gaede P, Vedel P, Parving HH et al. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 randomised study. Lancet 1999;353;617-22.
23. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
24. Harris MI, Klein R, Welborn TA et al. Onset of diabetes occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992;15:815-9.
25. Lauritzen T, Griffin S, Borch-Johnsen K et al for the ADDITION: Study Group. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24(suppl 3):S6-11.